CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Faculdade de Medicina (FM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
bachelor's at Medicina from Universidade do Estado do Pará (1989), master's at Alergia e Imunopatologia from Universidade de São Paulo (1995) and doctorate at Pathological Anatomy and Clinical Pathology from Universidade de São Paulo (1999). Has experience in Immunology, focusing on Applied Imunology, acting on the following subjects: hiv-1, htlv-i, subtipagem, imunologia and mielopatia associada ao htlv-i. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Los efectos del covid-19 |
| More itemsLess items |
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Human T-Cell Lymphotropic Virus Type 1 (HTLV-1), the first human retrovirus described, is the causative agent of a generally fatal T-cell Leukemia/Lymphoma and a progressive paraplegia called HTLV-1-associated myelopathy (HAM). ). There are at least 5-10 million people living with HTLV-1 (PVHTLV-1) in the world, almost more than a million in Brazil. Vertical transmission is perhaps the mo…
The prognosis of HAND presents a difficult approach, especially in the first stage of the disease, which may prevent early treatment and prevention of more severe forms. HIV can remain latent in the CNS for many years and subclinical infection associated with comorbidities (e.g., metabolic syndrome, drug use and Hepatitis C), as well as lead to immune activation, and low-grade chronic imm…
The HTLV-1 human oncogenic retrovirus infects 10-20 million worldwide, with more than 1 million carriers living in Brazil [1]. Five to 10 percent of infected individuals will develop an HTLV-1 associated disease: Adult T cell Leukemia (ATL), an aggressive lymphoproliferation of CD4+ T cells of poor prognosis (mean survival time of 6 months in the acute form), or HTLV-1 associated Myelopat…
In 2019, an outbreak of respiratory disease associated with a new coronavirus, SARS-CoV-2, started in the city of Wuhan, China. Since then, this highly transmissible virus has motivated extreme isolation measures worldwide, in an attempt to mitigate the infection of entire populations, concomitantly saturating medical services and collapsing health systems. Several coronaviruses are assoc…
Introduction: HTLV-1 was described in 1980, and has been mainly related to the causative agent of ATL and HAM / TSP, in addition to other inflammatory diseases. It is estimated that 15 to 25 million people worldwide are infected with HTLV-1. However, most of them remain asymptomatic. Immune and genetic factors of the host are related to the development of HAM/TSP, but there are no studies…
(Only some records are available in English at this moment)
STLV-1, Simian T-Cell Lymphotropic Virus type 1, shares genomic similarity with HTLV-1, making it a relevant model for genome editing studies. CRISPR-Cas9 technology has been crucial in genetic editing of HIV-1, but there is a scarcity of studies applying this strategy to the HTLV-1 genome. Furthermore, investigating cGAS/STING activation pathways can provide insights into inflammation an…
The diagnosis of the HIV associated neurocognitive disturbances (HAND) is difficult, especially in the first stage of the disease, preventing the early treatment and prevention of more severe forms. HIV can remain latent in the CNS for many years, and a subclinical infection associated with comorbidities (eg, metabolic syndrome, drug use and hepatitis C) may lead to immune activation and …
(Only some records are available in English at this moment)
Brazil is highly endemic for human T-cell lymphotropic virus type 1 (HTLV-1) and accounts for nearly more than one in ten infections in the world (almost one million). Mother-to-child transmission (MTCT) of HTLV is the principal transmission route and causes lifelong infection, high morbidity, high mortality disease including Adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy (H…
Introduction: HTLV-1 was described in 1980 and identified as the causative agent of ATL and HAM/TSP, in addition to other inflammatory diseases. It is estimated that 15 to 25 million people worldwide are infected with HTLV-1. However, most of them remain asymptomatic. Host immune and genetic factors have been associated to HAM/TSP pathogenesis, but large genome-wide studiesare lacking. …
| 2 / 2 | Ongoing grants |
| 30 / 19 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 35 / 15 | Completed scholarships in Brazil |
| 2 / 2 | Completed scholarships abroad |
| 71 / 40 | All research grants and scholarships |
| Associated processes | |